Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) CEO John F. Crowley sold 11,346 shares of the firm’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $8.00, for a total value of $90,768.00. Following the transaction, the chief executive officer now owns 932,807 shares in the company, valued at $7,462,456. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Amicus Therapeutics stock traded up $0.55 during trading on Tuesday, reaching $8.43. The company’s stock had a trading volume of 2,263,778 shares, compared to its average volume of 3,455,408. The company has a quick ratio of 3.81, a current ratio of 4.00 and a debt-to-equity ratio of 1.63. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -8.69 and a beta of 1.41. Amicus Therapeutics, Inc. has a 1-year low of $5.91 and a 1-year high of $12.63. The company has a 50-day simple moving average of $7.87 and a two-hundred day simple moving average of $9.23.
Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). The business had revenue of $78.72 million during the quarter, compared to analyst estimates of $76.97 million. Amicus Therapeutics had a negative return on equity of 95.05% and a negative net margin of 84.97%. During the same period in the previous year, the business earned ($0.25) EPS. As a group, analysts anticipate that Amicus Therapeutics, Inc. will post -0.89 earnings per share for the current year.
FOLD has been the topic of several research reports. StockNews.com initiated coverage on Amicus Therapeutics in a report on Thursday, March 31st. They set a “hold” rating on the stock. SVB Leerink dropped their target price on Amicus Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Thursday, February 24th. Finally, The Goldman Sachs Group initiated coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They set a “neutral” rating on the stock. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $15.00.
Amicus Therapeutics Company Profile (Get Rating)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
- Get a free copy of the StockNews.com research report on Amicus Therapeutics (FOLD)
- It’s Time To PLAY With Dave & Buster’s
- Seagate Technology: Improved Fundamentals & Recovering Technicals
- It’s A Sweet Time To Buy The J.M. Smucker Co.
- Don’t Rush Out To Buy G-III Apparel
- Target’s Warning Is Dire News For The S&P 500
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.